John Maraganore, Alan Spoon, John Green, Tom DiLenge

Jun 01, 2006

Premium

Archemix, a developer of aptamer-based therapeutics, said this week that John Maraganore has been appointed to its board of directors.

Maraganore is currently president and CEO of Alnylam Pharmaceuticals.

LRN, a provider of corporate ethics, compliance, and governance solutions, said this week that it has appointed Alan Spoon to its board.

Spoon is managing general partner for Polaris Venture Partners, an institutional investor in Alnylam Pharmaceuticals.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Vivo Validation of Optical Probes

Ex Vivo Imaging Quick Start Guide

Nov

05

Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Main menu